C10

C10 is a designation used for at least two distinct experimental small molecule agents currently in the preclinical stage. The first is a histamine H1 receptor antagonist initially developed by the University of Bayreuth and subsequently by the University of Kansas. This agent is being investigated for its potential therapeutic application in allergic and inflammatory conditions. The second agent, also identified as C10 in scientific literature, is a synthetic derivative of calenduloside E (a pentacyclic triterpenoid saponin) hybridized with a ticagrelor-derived fragment via a PEG chain. This compound targets heat shock protein 90 beta (HSP90β) and has demonstrated protective effects against ox-LDL-induced human umbilical vein endothelial cell (HUVEC) injury, suggesting potential utility in the treatment of atherosclerosis.